Biogen (BIIB) EBT Growth (1y) (2010 - 2026)
Powered by 
Analysis
Biogen (BIIB) EBT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 76.53% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -522.15% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 8.48% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 0.60% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 88.92% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 6.23% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 530.43% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -82.20% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 96.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -82.20% |
| Mar 31, 2026 | 21.37% |
| Dec 31, 2025 | -119.21% |
| Sep 30, 2025 | 23.57% |
| Jun 30, 2025 | 6.48% |
| Mar 31, 2025 | -33.05% |
| Dec 31, 2024 | -0.03% |
| Sep 30, 2024 | 419.41% |
| Jun 30, 2024 | -1.33% |
| Mar 31, 2024 | 6.05% |
| Dec 31, 2023 | -51.71% |
| Sep 30, 2023 | -110.30% |
| Jun 30, 2023 | -44.22% |
| Mar 31, 2023 | 26.17% |
| Dec 31, 2022 | 49.09% |
| Sep 30, 2022 | 371.01% |
| Jun 30, 2022 | 118.09% |
| Mar 31, 2022 | -25.61% |
| Dec 31, 2021 | 14.76% |
| Sep 30, 2021 | -69.61% |